Intellia develops CRISPR gene editing treatments for severe diseases, with lead candidates in late stage clinical trials. It last closed at $9.78 on Nov 17, down 0.81% on the day. The average 12-month price target from 3 analysts is $15.33 (+56.8% from the last close), with a high of $25.00 and a low of $8.00. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 1 hold, 1 sell).
Each firm's latest rating on NTLA in the past 90 days
Average 12-month target
$15.33
▲ 56.8% upside
Based on 3 analysts who set a price target on NTLA in the past 90 days. The average target is $15.33, with a high of $25.00 and a low of $8.00, compared with the last close of $9.78.
Highest target$25.00
Average target$15.33
Lowest target$8.00
Latest rating changes
BarclaysInitiated
Oct 6Sell$8
WedbushTarget lowered
Sep 9Hold$17 → $13
HC Wainwright & Co.Reiterated
Sep 9Buy$25
Evercore ISI GroupUpgrade
Aug 7Buy$24
Wolfe ResearchDowngrade
Jul 16Sell$9
Date
Firm
Action
Rating
Price target
Oct 6
Barclays
Initiated
Sell
$8
Sep 9
Wedbush
Target lowered
Hold
$17 → $13
Sep 9
HC Wainwright & Co.
Reiterated
Buy
$25
Aug 7
Evercore ISI Group
Upgrade
Buy
$24
Jul 16
Wolfe Research
Downgrade
Sell
$9
Loading…
Technical Analysis
NTLA · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 17% below its 20 day and 21% below its 50 day average. It is 32% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot S1 at $9.56, and the nearest resistance the Pivot at $9.90.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.4%/day
Key levels
$18.4852 week high+89.0%
$12.92200 day average+32.1%
$12.32100 day average+26.0%
$12.00Swing high (Oct 20)+22.7%
$11.8050 day average+20.7%
$11.4720 day average+17.3%
$10.12Pivot R1+3.5%
$9.90Pivot+1.2%
$9.78Last close
$9.56Pivot S1−2.2%
$7.9552 week low−18.7%
Indicators
RSI (14)
37.33
Weak, oversold below 30
Neutral
MACD
-0.51
Below its signal line
Bearish
Stochastic
2.6
Near the bottom of its range
Oversold
ADX (14)
13.7
No clear trend
Williams %R
-97.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-153.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−17.5%
Change over 10 sessions
Bearish
ATR (14)
$0.82
Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 19.3%/day
Key levels
$18.4852 week high+89.0%
$12.92200 day average+32.1%
$12.32100 day average+26.0%
$12.00Swing high (Oct 20)+22.7%
$11.8050 day average+20.7%
$11.4720 day average+17.3%
$10.12Pivot R1+3.5%
$9.90Pivot+1.2%
$9.78Last close
$9.56Pivot S1−2.2%
$7.9552 week low−18.7%
Indicators
RSI (14)
40.38
Middle of its range
Neutral
MACD
-0.64
Below its signal line
Bearish
Stochastic
10.0
Near the bottom of its range
Oversold
ADX (14)
10.6
No clear trend
Williams %R
-97.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-177.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−16.7%
Change over 10 sessions
Bearish
ATR (14)
$1.89
Typical daily range, 19.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for NTLA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NTLA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow NTLA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NTLA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTLA is in one of them and how their past NTLA trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Intellia Therapeutics
Intellia is a biopharmaceutical company based in Cambridge, Massachusetts, that develops treatments using CRISPR gene editing. Its lead candidates are designed to address the underlying cause of rare, severe diseases, including hereditary angioedema and ATTR amyloidosis, and are given as a single intravenous infusion. The company's lead candidates are in late stage clinical trials, and it is preparing for possible commercial launches aimed at patients with these conditions. It also works with partners, such as Regeneron, on additional programs.